IDO1 and head and neck squamous cell carcinoma: In turn, IDO inhibition by 1-MT or dinaciclib, identified as an indirect inhibitor of this enzyme, in GBM and head and neck squamous cell carcinomas revealed a synergistic effect co-administered with temozolomide (Figure 3) [85,88,150].